GLORY
30.9.2021 12:32:06 CEST | Business Wire | Press release
Glory, a global leader in cash technology solutions, today announced the launch of its new cloud-based software suite, UBIQULAR, designed to enable enhanced decision making based on data driven insight. The ‘Software As A Service’ (SaaS) solutions are tailored for the FI and retail markets.
The UBIQULAR suite reflects Glory’s continued goal of delivering greater insight and actionable intelligence around the cash being processed through its customers’ businesses and enabling them to unlock greater value from their Glory equipment. This is achieved via the use of analytics and management information, remote monitoring and management of devices and the delivery of automated cash forecasting that optimises cash inventories and working capital. Combining the analytical power of UBIQULAR with IoT enabled devices means Glory can deliver truly connected services. The secure cloud-based solutions effortlessly scale with customers’ businesses.
Ed Brindley, Business Director at Glory Global Solutions explained ‘The new UBIQULAR solutions enable an enhanced user experience via connected devices coupled with advanced data management. UBIQULAR services bring higher levels of efficiency to our customers and allow them to focus on what matters most - their core business. At launch the UBIQULAR suite offers customers a comprehensive range of value-added services, and we have built in the capacity to allow future expansion in line with our customers’ evolving requirements.’
The launch of UBIQULAR is an important milestone, signalling Glory’s growing focus on helping its FI and Retail clients derive maximum value from their investment in cash automation. Whether monitoring and managing a fleet of devices, increasing the effectiveness of business processes, optimizing cash inventories or raising the level of regulatory and security compliance, UBIQULAR delivers cash in high resolution.
- ENDS -
About GLORY
As a global leader in cash technology solutions, we provide the financial, retail, QSR, cash center and gaming industries with confidence that their cash is protected and always working to help build a stronger business.
Our cash automation technologies and process engineering services help businesses in more than 100 countries optimize the handling, movement and management of cash. While we span the globe, we personally engage with each customer to address their unique challenges and goals — enhancing staff efficiency, reducing operating costs and enabling a more rewarding customer experience.
Employing over 11,000 professionals worldwide with dedicated R&D and manufacturing facilities across the world, GLORY is built on a rich customer-focused, technology-driven heritage spanning almost a hundred years.
For further information please visit www.glory-global.com or follow us on Twitter: http://twitter.com/glory_global .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210930005400/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
PNCC Selects LotusFlare to Power Digital BSS and Commerce Platform for New 4G/5G Standalone Network26.2.2026 13:04:00 CET | Press release
LotusFlare, a provider of a cloud-native, AI-driven digital commerce and monetization platform for communications service providers (CSPs), today announced that Palau National Communications Corporation (PNCC) has selected it to provide a comprehensive commerce and monetization platform, including a full-stack digital business support system (dBSS) as part of PNCC’s broader 4G/5G Standalone (SA) network modernization programme. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260226869218/en/ Palau National Communications Corporation (PNCC) The LotusFlare solution will support PNCC subscribers across mobile, fixed broadband, and digital TV services, while enabling unique multi-tenant capabilities aligned with PNCC’s long-term digital and regional strategy. PNCC has embarked on a comprehensive technology modernization program focused on increasing speed-to-market, enhancing customer experience, and long-term operational efficie
GoldState Music and Bridgepoint Announce Strategic Partnership Targeting Growth Investments26.2.2026 13:00:00 CET | Press release
Capital will support GoldState Music’s Growth Strategy which will invest in scalable, profitable music-oriented businesses across the music value chainBridgepoint commits a significant investment as lead investor in GoldState’s Growth Strategy Bridgepoint, one of the world’s leading mid-market investors, today announced that it has entered into a strategic partnership with GoldState Music, a premier music investment platform, committing a significant investment as lead investor in GoldState’s Growth Strategy. The capital will support a dedicated investment programme focused on building and scaling high-quality music-oriented businesses globally. GoldState Music is a private investment firm founded in 2022 by industry veteran Charles Goldstuck, who played an integral role in the development of many music enterprises as well as in the careers of numerous major artists and songwriters. The company’s Growth Strategy is focused on investing in and scaling growing businesses operating in the
Kairos Pharma, Ltd. Announces Signing of Term Sheet for Strategic Asset Acquisition of Two Clinical Oncology Assets from Celyn Therapeutics26.2.2026 13:00:00 CET | Press release
Transformative clinical pipeline transaction will add CL-273, a pan-EGFR inhibitor, and CL-741, a Phase 1-Ready c-MET inhibitor, to Kairos Pharma's clinical portfolio to target multi-billion dollar lung cancer market. Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, today announces the signing of a term sheet for a strategic asset acquisition with Celyn Therapeutics, Inc., a privately held biotechnology company backed by OrbiMed and Torrey Pines Investment. Under the proposed terms of the agreement, Kairos Pharma will acquire worldwide rights to two highly differentiated, clinical-stage oncology assets targeting non-small cell lung cancer (NSCLC): CL-273, a pre-IND, reversible, wild-type-sparing pan-EGFR inhibitor, and CL-741, a Phase 1-ready, orally available type IIb c-MET kinase inhibitor. John Yu, M.D., Kairos Pharma Chief Executive Officer, commented: "We anticipate this acquisition will significantly
Amazfit Introduces the Active 3 Premium: Turning Daily Movement into Meaningful Progress for Entry-Level Runners26.2.2026 13:00:00 CET | Press release
Premium materials, a 12-day battery life and new running features provide support for those kicking off their running journey Amazfit, a leading global smart wearable brand owned by Zepp Health, today announced the Amazfit Active 3 Premium, a compact, 4-button smartwatch designed as an entry point into structured running and hybrid training. Made for athletes building consistency across different forms of training, the Active 3 Premium supports road running and hybrid routines that combine endurance, strength, and studio-based workouts. Its compact design makes it easy to train across environments, from neighborhood runs to studio floors, offering a capable, approachable experience without feeling overbuilt or intimidating. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260226378156/en/ Made for athletes building consistency across different forms of training, the Active 3 Premium supports road running and hybrid routines th
Wyss Geneva Spin-Off Clee Medical Secures Seed Financing to Bring Real-Time Vision to Brain Surgery26.2.2026 12:49:00 CET | Press release
The Wyss Center for Bio and Neuroengineering Geneva announced today the successful closing of the Seed financing round of Clee Medical SA, a Swiss neurotechnology spin-off developing ultra-high-resolution real-time intraoperative imaging for brain surgery. The round was led by High-Tech Gründerfonds (HTGF), with participation from Zürcher Kantonalbank (ZKB), Kickfund, FONGIT, and Venture Kick joining existing investors Wyss Center Geneva. Clee Medical spun-out from Wyss Geneva’s Minimally Invasive Intracranial Access (MICA) research project in December 2024. Its flagship platform, Neuro Access, combines OCT imaging with advanced navigation to help neurosurgeons visualize brain anatomy and critical structures in real time during stereotactic procedures. “Clee Medical not only holds the promise of improving patient outcomes but also highlights Wyss Geneva’s dedication to bridging the gap between scientific discovery and real-world impact.” Dr. Erwin Böttinger, CEO, Wyss Geneva “Neurosurg
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom